Clinical Trial Detail

NCT ID NCT03077828
Title Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Northwestern University

Hodgkin's lymphoma


Carboplatin + Etoposide + Ifosfamide + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.